Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation

Abstract Background Empagliflozin (EMPA) has demonstrated efficacy in providing cardiovascular benefits in metabolic diseases. However, the direct effect of EMPA on autophagy in obesity-related cardiac dysfunction remains unclear. Therefore, this study aimed to determine changes in cardiac autophagy...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Youhong Luo, Tongtong Ye, Hongzhan Tian, Hongwei Song, Chengxia Kan, Fang Han, Ningning Hou, Xiaodong Sun, Jingwen Zhang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-09-01
Serie:	Lipids in Health and Disease
Soggetti:	Obesity-related cardiac dysfunction Empagliflozin SIRT3 Autophagy
Accesso online:	https://doi.org/10.1186/s12944-024-02293-9
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!